Skip to main content
Clinical Trials/NCT05015114
NCT05015114
Completed
Not Applicable

Prevalence and Factors of Sarcopenia in Patients With Primary Sjogren's Syndrome

Acibadem University1 site in 1 country50 target enrollmentAugust 12, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sarcopenia
Sponsor
Acibadem University
Enrollment
50
Locations
1
Primary Endpoint
Grip Strength
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Sarcopenia is a progressive condition characterized by decline in muscle strength and muscle mass. Although the mechanism of sarcopenia has not been fully elucidated, it may be caused by protein-poor diet, vitamin D deficiency, hormonal changes, increase in inflammatory cytokine level and oxidative stress. For this reason, it is thought that determining the prevalence of sarcopenia in rheumatological diseases with chronic inflammation and protecting patients from possible comorbidities with appropriate interventions may be an important factor in maintaining and improving the functional levels and quality of life of patients.

The aim of our study was to investigate the prevalence and its associated factors of sarcopenia in individuals with primary Sjögren's Syndrome.

Registry
clinicaltrials.gov
Start Date
August 12, 2021
End Date
May 5, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Acibadem University
Responsible Party
Principal Investigator
Principal Investigator

Özgül Öztürk

Assistant Professor

Acibadem University

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with primary Sjogren's syndrome by an experienced rheumatologist according to European League Against Rheumatism (EULAR) ve American College of Rheumatology (ACR) criteria
  • Being 40 years or older.

Exclusion Criteria

  • Pregnancy,
  • Malignancy,
  • Presence of other rheumatological diseases,
  • Presence of diabetes mellitus
  • Presence of neurological problems
  • Presence of osteoarthritis

Outcomes

Primary Outcomes

Grip Strength

Time Frame: 1 day

Grip strength will be evaluated with JAMAR dynamometer. The patient is positioned in a chair with the elbow flexed to 90 degrees and the wrist in a neutral position, and he/she is asked to grip as strong as he/she can do for 3 seconds. The test is repeated 3 times and the highest value is recorded.

Gait Speed

Time Frame: 1 day

The patient will be asked to walk 4-meters for two times. The shortest time to walk through this distance will be recorded.

5 Times Sit to Stand Test

Time Frame: 1 day

This test includes the calculation of the time it takes to sit and get up from the chair 5 times while the arms are crossed over the shoulders.

Muscle Mass

Time Frame: 1 day

Muscle mass will be calculated via bioimpedance analysis method. Fat Free Mass will be recorded using TANITA BC 532 Bioimpedance Device and Skeletal Muscle Mass and Skeletal Muscle Mass will be calculated.

Secondary Outcomes

  • EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)(1 day)
  • EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)(1 day)
  • Malnutrition Evaluation(1 day)

Study Sites (1)

Loading locations...

Similar Trials